Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404960 · ClinicalTrials.gov registry record · Phase 1
Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT03404960: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03404960 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03404960, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on patients and their pancreatic cancer.
Interventions
- DRUG Niraparib + Nivolumab
- DRUG Niraparib + Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2024-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03404960
The ClinicalTrials.gov registry entry for NCT03404960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Niraparib + Nivolumab is the first listed.
NCT03404960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03404960 about?
NCT03404960 is a clinical study titled "Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy". The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on patients and their pancreatic cancer.
What is the current status of trial NCT03404960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2018-01-31. Estimated completion is 2024-10-09.
What interventions are being tested in trial NCT03404960?
The interventions under investigation include: Niraparib + Nivolumab (DRUG), Niraparib + Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03404960?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.